Stock BNN BRAIN BIOTECH AG
Add to a list
To use this feature you must be a member
Log inSign up

BRAIN Biotech AG Stock

Equities

BNN

DE0005203947

Environmental Services & Equipment

Market Closed - Xetra
Other stock markets
 11:36:14 2024-05-24 am EDT 		5-day change 1st Jan Change
2.76 EUR +1.10% Intraday chart for BRAIN Biotech AG +0.36% -24.59%
Apr. 16 Brain Biotech Plans Merger by Absorption of AnalytiCon Discovery MT
Mar. 05 BRAIN Biotech AG and AMSilk GmbH Announce the Successful Completion of the First Phase of A Development Collaboration CI

Financials

Sales 2024 * 62.56M 67.85M Sales 2025 * 70.97M 76.97M Capitalization 60.3M 65.39M
Net income 2024 * -3M -3.25M Net income 2025 * - 0 EV / Sales 2024 * 1.36 x
Net Debt 2024 * 24.73M 26.82M Net Debt 2025 * 23.42M 25.4M EV / Sales 2025 * 1.18 x
P/E ratio 2024 *
-17.2 x
P/E ratio 2025 *
-158 x
Employees 311
Yield 2024 *
-
Yield 2025 *
-
Free-Float 39.38%
More Fundamentals * Assessed data

Chart BRAIN Biotech AG

Dynamic Chart

Latest news about BRAIN Biotech AG

Brain Biotech Plans Merger by Absorption of AnalytiCon Discovery MT
BRAIN Biotech AG and AMSilk GmbH Announce the Successful Completion of the First Phase of A Development Collaboration CI
BRAIN Biotech AG Reports Earnings Results for the First Quarter Ended December 31, 2023 CI
BRAIN Biotech AG Reports Earnings Results for the Full Year Ended September 30, 2023 CI
BRAIN Biotech AG Reports Earnings Results for the Third Quarter and Nine Months Ended June 30, 2023 CI
BRAIN Biotech AG Reports Earnings Results for the Second Quarter and Six Months Ended March 31, 2023 CI
Transcript : BRAIN Biotech AG, Q2 2023 Earnings Call, May 25, 2023
BRAIN Biotech to Look Acquisitions CI
BRAIN Biotech AG acquired remaining 17.8% stake in Biocatalysts Limited for ?9.6 million. CI
SolasCure Limited announced that it has received £10.9 million in funding from Seneca Partners Limited, BRAIN Biotech AG, Eva Pharma Consultants Ltd, Wealth Club Limited and another investor CI
BRAIN Biotech AG announced that it expects to receive ?5 million in funding from MP Beteiligungs-Gmbh CI
BRAIN Biotech AG Reports Earnings Results for the First Quarter Ended December 31, 2022 CI
BRAIN Biotech Ends Contract with Roquette Frères on Natural Sweetener Joint Development MT
BRAIN Biotech Unit to Focus on Developing New Therapies Via Genome-editing Technology MT
BRAIN Biotech AG Announces Executive Changes CI
More news

Latest transcript on BRAIN Biotech AG

Logo BRAIN Biotech AG
BRAIN Biotech AG, Q2 2023 Earnings Call, May 25, 2023
More transcripts

Analyst Recommendations on BRAIN Biotech AG

ANALYST RECOMMENDATIONS : Crowdstrike, Fortinet, Hiscox, L Brands, Nasdaq 100.... Our Logo
More recommendations

Press releases BRAIN Biotech AG

AFR: BRAIN Biotech AG: Preliminary announcement of the publication of financial reports according to Articles 114, 115, 117 of the WpHG [the German Securities Act] EQ
BRAIN Biotech AG takes next step to optimize group structure EQ
Beverages made from vine leaves: Sustainable drinking pleasure based on agricultural side streams EQ
Results of the Annual General Meeting 2024 for the financial year 2022/23 of BRAIN Biotech AG EQ
Collaboration between BRAIN Biotech and AMSilk, Protein engineering successfully improves structural proteins for performance materials AQ
More press releases

News in other languages on BRAIN Biotech AG

AFR: BRAIN Biotech AG: Vorabbekanntmachung über die Veröffentlichung von Finanzberichten gemäß § 114, 115, 117 WpHG
BRAIN Biotech AG unternimmt nächsten Schritt zur Optimierung der Gruppenstruktur
BRAIN Biotech AG unternimmt nächsten Schritt zur Optimierung der Gruppenstruktur
Getränke aus Weinblättern: Nachhaltiger Trinkgenuss auf Basis landwirtschaftlicher Seitenströme
Getränke aus Weinblättern: Nachhaltiger Trinkgenuss auf Basis landwirtschaftlicher Seitenströme
More news

Quotes and Performance

1 day+1.10%
1 week+0.36%
Current month-1.43%
1 month-1.08%
3 months-28.87%
6 months-24.59%
Current year-24.59%
More quotes

Highs and lows

1 week
2.65
Extreme 2.65
2.90
1 month
2.59
Extreme 2.59
2.90
Current year
2.51
Extreme 2.51
4.19
1 year
2.51
Extreme 2.51
5.06
3 years
2.51
Extreme 2.51
11.00
5 years
2.51
Extreme 2.51
14.28
10 years
2.51
Extreme 2.51
27.75
More quotes

Managers and Directors - BRAIN Biotech AG

Managers TitleAgeSince
Adriaan Moelker CEO
 Chief Executive Officer 60 20-01-31
Michael Schneiders DFI
 Director of Finance/CFO 54 20-04-30
Alexander Pelzer CTO
 Chief Tech/Sci/R&D Officer 38 13-12-31
Members of the board TitleAgeSince
Michael Majerus CHM
 Chairman 63 19-03-06
Stephen Catling BRD
 Director/Board Member 59 20-10-13
Wiltrud Treffenfeldt BRD
 Director/Board Member 70 20-10-13
More insiders

Quotes

Date Price Change Volume
24-05-24 2.76 +1.10% 18,454
24-05-23 2.73 -0.36% 18,454
24-05-22 2.74 0.00% 11,014
24-05-21 2.74 -2.49% 18,962
24-05-20 2.81 +2.18% 423

Delayed Quote Xetra, May 24, 2024 at 11:36 am EDT

More quotes

Company Profile

BRAIN Biotech AG, formerly known as BRAIN Biotechnology Research and Information Network AG is a Germany-based industrial biotechnology company develops and brings to market biological ingredients for Nutrition & Health, SkinCare and Industrial BioSolutions. Research & Development activities focus on bioactive natural compounds, tailored enzymes and high-performance microorganisms.
Sector
Environmental Services & Equipment
Calendar
2024-05-28 - Q2 2024 Earnings Release
More about the company

Income Statement Evolution

More financial data

Ratings for BRAIN Biotech AG

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
2.76 EUR
Average target price
10.98 EUR
Spread / Average Target
+297.64%
Consensus

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Environmental Biotechnology

1st Jan change Capi.
BRAIN BIOTECH AG Stock BRAIN Biotech AG
-24.59% 65.45M
AFYREN Stock Afyren
+25.94% 70.61M
Environmental Biotechnology
  1. Stock Market
  2. Equities
  3. BNN Stock